secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001437749-25-006898
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health to sell oncology testing assets to Labcorp for up to $225M
----------------------------------------------------------------------

- Purchase price: $192.5M at closing plus up to $32.5M in earnout based on performance.
- Divested assets generate ~$85-100M in annual revenue; deal expected to close H2 2025.
- BioReference retains core NY/NJ clinical testing and 4Kscore franchise (~$300M 2024 revenue).
- Labcorp expects acquisition to be accretive to earnings in year one.
- Transaction includes customary closing conditions and state regulatory approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774925006898/0001437749-25-006898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774925006898/opk20250305c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-006898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer